AI in Lung Cancer Screening: How Nodule Software Fits the Workflow

The short answer: In a lung cancer screening program, AI sits between acquisition and the report. The low-dose CT arrives, the software flags candidate nodules for the radiologist to confirm or dismiss, places diameter and volume measurements, pulls the matching nodule from the prior study for growth comparison, and drafts the structured report with those numbers already in it. The radiologist confirms the nodules, assigns the Lung-RADS category and signs. Category assignment and the follow-up recommendation stay with the radiologist.

Screening is where nodule AI makes the most sense, and not for the reason vendors usually lead with. The pitch is normally about finding what a radiologist would miss. The day-to-day value is more mundane: a screening read is a measurement and documentation exercise repeated dozens of times a day, and most of the minutes go into work that is mechanical rather than diagnostic.

What makes a screening read different

A diagnostic chest CT asks an open question. A screening low-dose CT asks a closed one, in a fixed format, on a patient who will come back next year and be compared against today.

That structure has three consequences. The read is protocol-driven, so the same steps happen every time. It is comparison-heavy, because the number that matters is usually growth rather than size. And it is documentation-heavy, because the output has to be a structured report with a category that drives what happens to the patient next.

None of that is hard. All of it is repetitive, and repetition at volume is where consistency quietly degrades. Keeping the same attention on study fifteen as on study one is the actual difficulty of a screening list, and it is a difficulty software is reasonably well suited to help with.

Where AI fits in the workflow

Read down the right-hand column and the division is clear enough. The software does the finding, measuring and typing. The radiologist does the judging. The line sits exactly where it should: everything requiring clinical judgment stays with the person who carries the responsibility for it.

Does AI assign the Lung-RADS category?

It should not, and a well-built tool does not. Category assignment is a clinical judgment that folds in nodule characteristics, growth, comparison against priors and the patient context, and it drives a real downstream decision about what happens to that patient.

What software can do is put every input to that judgment in front of the radiologist at once: the confirmed nodules, the measurements, the prior comparison, all placed in the structured template. The radiologist then assigns the category. If a vendor tells you their product assigns categories autonomously, ask very carefully what "assigns" means and who is accountable for the result.

The useful test for any screening AI: does it reduce the time spent on measuring and typing, without moving any part of the clinical judgment away from the radiologist? If it does the first, it is worth having. If it does the second, it is a liability.

Second reader, and what the research actually says

The most common deployment is as a second-reader prompt: the radiologist reads normally, and the software flags candidates in parallel for review.

The literature on this is more nuanced than either the enthusiasts or the skeptics present it. Systematic reviews of AI for nodule and cancer detection in CT screening consistently find that these tools tend to increase sensitivity, particularly for smaller and subtler nodules, and that the gain often comes at some cost to specificity. In a screening context that trade has a specific meaning: more nodules surfaced means more surveillance imaging for nodules that would never have become cancer, with the follow-up burden and patient anxiety that come with it.

Reviews also note that performance drops when a tool is applied to a population that differs from its training data, which is the single most important caveat for a buyer. A published figure from one cohort tells you about that cohort. It does not tell you how the software will behave on your patients, your scanners and your protocols.

The practical conclusion is not that the research is discouraging. It is that the research cannot answer the question you actually have, which is about your program specifically. That question is answered by running the tool in shadow mode on your own studies for a few weeks and comparing what it surfaced against what your radiologists did.

Incidental nodules matter more than the screening list

Formal screening programs get the attention, but a large share of nodules turn up on chest CTs ordered for something else entirely: trauma, pulmonary embolism workup, pre-operative imaging, cardiac studies. Those nodules land in the middle of a study nobody was reading for nodules, and they get documented with varying consistency.

This is arguably where automated flagging earns its keep. On the screening list, the radiologist is already looking for nodules with full attention, so the marginal benefit is real but modest. On a trauma chest CT at 11pm, a prompt that surfaces an incidental nodule and carries the measurement into the report is the difference between a documented finding with a follow-up recommendation and a note in a paragraph nobody actions.

The follow-up loop is where programs most often leak, and it is worth auditing separately from anything AI-related. Software that reliably gets the nodule into the structured report with a measurement attached at least makes the leak visible.

The parts of a screening program AI does not touch

Worth saying plainly, because it is easy to buy a nodule tool and expect a program.

Eligibility and enrollment. Determining who qualifies, running shared decision-making conversations and documenting them is administrative and clinical work that imaging software has nothing to do with.

Registry reporting. Screening programs carry data submission obligations. That is a data pipeline problem, not an imaging problem.

Getting prior imaging in the first place. Comparison against a prior only works if the prior is available, and in practice outside imaging and records frequently arrive as scanned faxes and PDFs that have to be handled by hand before anyone can compare anything. Programs that run smoothly usually have some way to pull the structured data out of those scanned documents rather than leaving a coordinator to retype it, and the time saved there often exceeds anything gained inside the read itself.

Tracking patients through follow-up. Making sure the twelve-month recall actually happens is a tracking and outreach function. It is the part of screening most likely to fail, and it is not an imaging AI problem.

What to ask a vendor about nodule AI

1. Screening only, or incidental too? Some products are tuned for low-dose screening protocols and behave differently on routine contrast-enhanced chest CT. Most of your nodules will come from the second.
2. What does it measure, and how? Diameter, volume, or both. Volume doubling time is far more useful for growth assessment, and it requires consistent segmentation across studies.
3. How does prior comparison work? Automatic nodule matching against the prior study saves real time. Ask what happens when the prior was acquired on a different scanner or protocol, because that is the common case.
4. Where does the output land? In your reporting template with the nodule table populated, or in a separate viewer you have to transcribe from? Transcription undoes the benefit entirely.
5. What is the flag rate on studies like ours? Ask for it from a comparable program, then verify it yourself in a shadow period.
6. Which indications are cleared? Clearance is granted per indication, and a list of clearances is not a list of what the product does.

Our vendor evaluation guide covers the contract, integration and pilot questions that apply to any radiology AI purchase.

How Radiological.ai handles nodules

Radiological.ai reviews the chest CT and flags regions that look like suspected nodules for the radiologist to confirm or dismiss, places diameter and volume measurements on confirmed nodules, pulls the matching nodule from the prior study for growth comparison, and drafts the structured report into your template with the nodule table already populated. It works on screening low-dose CT and on incidental nodules found on routine chest CT.

The radiologist confirms every nodule, assigns the category, edits the impression and signs. We publish no accuracy figures, make no regulatory-status claims, and nothing the assistant produces is a diagnosis. Every flag is a prompt to look and every report is a draft.

See the detail on our AI lung nodule detection software page, or the broader chest CT workflow on AI CT scan analysis. If queue depth rather than nodule work is your bottleneck, AI triage radiology software covers the worklist side, and our implementation guide walks through running the shadow period properly.